Skip to main content

AI Proteins

Category: AI in Healthcare

AI Proteins pioneers programmable miniproteins—engineered from scratch with AI, robotics, and synthetic biology to create safer, more precise biologics for patients. AI Proteins was founded in 2021. The company is led by Chris Bahl. Based in Boston, United States. Team size: 37. Total funding raised: $59.7M. Latest round: Series A. Key investors include ["Mission BioCapital","Santé Ventures","Cobro Ventures","Lightchain Capital"].

Founded
2021
Headquarters
Boston, United States
Team size
37
Total funding
$59.7M

Value proposition

Rapid development of miniproteins with high specificity and efficacy, reducing costs and time-to-market for protein therapeutics through AI-driven de novo design

Products and solutions

["De novo miniproteins for oncology","Miniproteins for inflammatory diseases","Metabolic disease therapeutics","Partnership-driven custom protein designs","Multispecific agents","Targeted delivery systems"]

Unique value

Pioneering de novo design of miniproteins from scratch using AI-driven computational models and high-throughput experimental validation, creating proteins unconstrained by evolution

Target customer

Pharmaceutical companies, biotech firms, and research institutions seeking innovative protein-based therapeutics

Industries served

["Oncology","Inflammation","Metabolic Diseases","Biopharmaceutical Research","Diagnostics","Agriculture"]

Technology advantage

Integration of AI, robotics, and synthetic biology enables rapid iteration and optimization of miniproteins with precise functional properties, complete control over function, selectivity, stability, and pharmacology

How they differentiate

AI Proteins specializes in computational de novo design of miniproteins, leveraging AI and robotics for high-throughput development. Competitors like Absci Bio focus on AI-driven protein engineering for biologics, while Mopac Biologics emphasizes synthetic biology platforms for novel modalities

Main competitors

["Mopac Biologics","Absci Bio","Xaira Bio","Profluent Therapeutics"]

Key partnerships

["Bristol Myers Squibb ($400M collaboration for miniprotein-based therapeutics development)","Vivtex (strategic R&D collaboration for oral biologic therapies)","NSF-funded research initiatives in AI-driven protein design"]

Notable customers

["Bristol Myers Squibb"]

Major milestones

["$41.5M Series A funding in November 2025","Bristol Myers Squibb collaboration (2024)","Appointment of Chris Bahl as CEO (January 2025)","Presenting at PEGS Boston 2025"]

Growth metrics

37 employees as of 2025; partnered with Bristol Myers Squibb for a $400M collaboration; in vivo proof-of-concept across over 150 targets

Market positioning

Positioned as a pioneer in miniprotein therapeutics using AI-driven design, targeting high-value therapeutic areas with partnerships like Bristol Myers Squibb

Geographic focus

Competitors are primarily based in the US, with AI Proteins focused on Boston, Massachusetts, and others like Xaira Bio in Europe

Patents and IP

No specific patents listed in public sources; focus on proprietary AI algorithms and design platforms

About Chris Bahl

Founder, President, and Chief Scientific Officer of AI Proteins. Prior to founding AI Proteins, he was a founding faculty member at the Institute for Protein Innovation in Boston and held appointments at Boston Children's Hospital and Harvard Medical School. He is a renowned leader in the field of protein design and computational de novo protein design.

Official website: